Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1797592 | 1.00 | CHRNB4 (0.50) | CHRNB4CHRNA3CHRM3SLC6A9CARM1 | |
| SCHEMBL1797593 | 1.00 | CHRNB4 (0.50) | CHRNB4CHRNA3CHRM3SLC6A9CARM1 | |
| SCHEMBL13403259 | 0.98 | CHRNB4 (0.49) | CHRNB4CHRNA3CHRM3SLC6A9CARM1 | |
| SCHEMBL6648223 | 0.95 | CHRNB4 (0.55) | CHRNB4CHRNA3CHRM3CARM1PRMT6 | |
| SCHEMBL4781411 | 0.91 | CHRNB4 (0.46) | CHRNB4CHRNA3 | |
| SCHEMBL4725436 | 0.91 | CHRNB4 (0.46) | CHRNB4CHRNA3 | |
| SCHEMBL4725442 | 0.91 | CHRNB4 (0.46) | CHRNB4CHRNA3 | |
| SCHEMBL4780731 | 0.85 | SLC6A2 (0.43) | CHRNB4CHRNA3 | |
| SCHEMBL4780734 | 0.85 | SLC6A2 (0.43) | CHRNB4CHRNA3 | |
| SCHEMBL4794244 | 0.85 | SLC6A2 (0.43) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1161018-C | Pest control composition | ��˹��ŵ�� | 2004-08-11 | — | — | CN | claimed |
| US-20040146542-A1 | Non-therapeutical process for deterring vermin from warm-blooded animals, whereby 2-substituted-piperidine compound is is applied topically, together with a spreading additive, to the skin, the pelt or the plumage of the warm-blooded animal | FROELICH OLIVIER | 2004-07-29 | — | — | US | claimed |
| US-20020142023-A1 | Composition for keeping away vermin | NOVARTIS ANIMAL HEALTH US INC. | 2002-10-03 | — | — | US | claimed |
| EP-1087662-B1 | COMPOSITION FOR KEEPING AWAY VERMIN | NOVARTIS AG (CH) | 2002-04-10 | — | — | EP | claimed |
| CN-1302184-A | Composition for keeping away vermin | NOVARTIS AG (CH) | 2001-07-04 | — | — | CN | claimed |
| US-20010003646-A1 | Composition for keeping away vermin | FROELICH OLIVIER (FR) | 2001-06-14 | — | — | US | claimed |
| EP-1087662-A1 | COMPOSITION FOR KEEPING AWAY VERMIN | Novartis AG (CH) | 2001-04-04 | — | — | EP | claimed |
| WO-1999065311-A1 | COMPOSITION FOR KEEPING AWAY VERMIN | NOVARTIS AG (CH) | 1999-12-23 | — | — | WO | claimed |
| US-7951821-B2 | Devoided of activity on the opiate or 5-HT3 receptors, exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2; 2-Chloro-N-[(S)-phenyl-[(2S)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide | SANOFI-AVENTIS (FR) | 2011-05-31 | — | — | US | disclosed |
| EP-2261218-A2 | Process for preparing phenyl-, pyridinyl- or pyrimidinyl-substituted imidazoles | Eisai R&D Management Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20100234424-A1 | DERIVATIVES OF N-PHENYL(PIPERIDINE-2-YL) METHYL BENZAMIDE PREPARATION METHOD THEREOF AND APPLICATIONS OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-09-16 | — | — | US | disclosed |
| US-7790753-B2 | Derivatives of N-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-09-07 | — | — | US | disclosed |
| US-7750025-B2 | Derivatives of N-phenyl (piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-07-06 | — | — | US | disclosed |
| US-7326722-B2 | N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy | SANOFI-AVENTIS (FR) | 2008-02-05 | — | — | US | disclosed |
| EP-0429984-B1 | Indole derivatives | NISSHIN FLOUR MILLING CO (JP) | 1997-07-23 | — | — | EP | disclosed |
| EP-0572449-A1 | (AMIDOMETHYL)NITROGEN HETEROCYCLIC ANALGESICS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-12-08 | — | — | EP | disclosed |
| US-5254569-A | Side effect reduction; diuretics; anticonvulsants | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| WO-1992012128-A1 | (AMIDOMETHYL)NITROGEN HETEROCYCLIC ANALGESICS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-07-23 | — | — | WO | disclosed |
| US-5124324-A | Psychological disorders, 5-hydroxy tryptamine antagonists | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1992-06-23 | — | — | US | disclosed |
| EP-0429984-A2 | Indole derivatives | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1991-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040146542-A1 | Non-therapeutical process for deterring vermin from warm-blooded animals, whereby 2-substituted-piperidine compound is is applied topically, together with a spreading additive, to the skin, the pelt or the plumage of the warm-blooded animal | PLG, PFN1, CUTA | CHRNB4 4672/4885CHRNA3 4427/4885CHRM3 4660/4885 |
| US-20010003646-A1 | Composition for keeping away vermin | VMP1, SERPINC1, VIL1 | CHRNB4 4321/4885CHRNA3 4405/4885CHRM3 3879/4885 |
| US-20100234424-A1 | DERIVATIVES OF N-PHENYL(PIPERIDINE-2-YL) METHYL BENZAMIDE PREPARATION METHOD THEREOF AND APPLICATIONS OF SAME IN THERAPEUTICS | SNCA, GABRE, CHRNA5 | CHRNB4 101/4885CHRNA3 28/4885CHRM3 220/4885 |
| US-20020142023-A1 | Composition for keeping away vermin | VMP1, SERPINC1, VIL1 | CHRNB4 4321/4885CHRNA3 4405/4885CHRM3 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.